Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Rithi J. Chandy, Sarah G. Bridgeman, Brandon M. Godinich & Steven R. Feldman. (2023) New synthetic pharmacotherapeutic approaches to the treatment of moderate-to-severe plaque psoriasis in adults. Expert Opinion on Pharmacotherapy 24:8, pages 959-967.
Read now
Read now
Tammy Gonzalez & Alan B. Fleischer$suffix/text()$suffix/text(). (2022) Increased biologic utilization in Latino patients with psoriasis. Journal of Dermatological Treatment 33:2, pages 965-968.
Read now
Read now
Xiaoying Jia, Yang Zhao, Justin Carrico, Thor-Henrik Brodtkorb, Alan M. Mendelsohn, Simon Lowry, Steve Feldman, Jashin J. Wu & April W. Armstrong. (2022) Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment 33:2, pages 740-748.
Read now
Read now
Jashin J. Wu, Annie Guérin, Geneviève Gauthier & Murali Sundaram. (2017) Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. Journal of Dermatological Treatment 28:4, pages 290-298.
Read now
Read now
Ian TY Wong, Kam Shojania, Jan Dutz & Nicole W Tsao. (2016) Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 153-166.
Read now
Read now
Jose-Manuel Carrascosa, Ignacio Garcia-Doval, Beatriz Pérez-Zafrilla, Gregorio Carretero, Francisco Vanaclocha, Esteban Daudén, Pablo De la Cueva-Dobao, Isabel Belinchón, Merce Alsina, Jose-Luis López-Estebaranz, Marta Ferrán, Rosa Torrado, Raquel Rivera, Cristina Carazo, Lorena Barboza & Carlos Ferrándiz. (2015) Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice. Journal of Dermatological Treatment 26:6, pages 502-506.
Read now
Read now
Yue Zhao & Wei Lai. (2014) Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab. Patient Preference and Adherence 8, pages 865-872.
Read now
Read now
Kara Luersen, Tushar S. Dabade, Cameron E. West, Scott A. Davis & Steven R. Feldman. (2014) Phototherapy trends in dermatology. Journal of Dermatological Treatment 25:6, pages 487-488.
Read now
Read now
Maeve Lynch, Brian Kirby & Richard B Warren. (2014) Treating moderate to severe psoriasis – best use of biologics. Expert Review of Clinical Immunology 10:2, pages 269-279.
Read now
Read now
Brandon Shutty, Cameron West, Megan Pellerin & Steven Feldman. (2012)
Apremilast as a treatment for psoriasis. Expert Opinion on Pharmacotherapy 13:12, pages 1761-1770.
Read now
Read now
Articles from other publishers (40)
Elaine C. Siegfried, Lisa M. Arkin, Yvonne E. Chiu, Adelaide A. Hebert, Jeffrey P. Callen, Leslie Castelo‐Soccio, Dominic O. Co, Kelly M. Cordoro, Megan L. Curran, Austin M. Dalrymple, Carsten Flohr, Ken B. Gordon, Diane Hanna, Alan D. Irvine, Susan Kim, A. Yasmine Kirkorian, Irene Lara‐Corrales, Jill Lindstrom, Amy S. Paller, Melissa Reyes, Wendy Smith Begolka, Wynnis L. Tom, Abby S. Van Voorhees, Ruth Ann Vleugels, Lara Wine Lee, Olivia M. T. Davies & Heather A. Brandling‐Bennett. (2023) Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines. Pediatric Dermatology.
Crossref
Crossref
Shin Yi Ooi, Min Moon Tang, Chai Har Loo, Wooi Chiang Tan & Suganthy Robinson. (2023) Utilization of phototherapy and treatment response in adults with psoriasis: Data from the Malaysian Psoriasis Registry. Photodermatology, Photoimmunology & Photomedicine 39:2, pages 155-158.
Crossref
Crossref
François Aubin, Eve Puzenat, Fabien Pelletier, Charlée Nardin & Florence Castelain. (2023) Comment on “Trends in phototherapy utilization among Medicare beneficiaries in the United States, 2000 to 2015”. Journal of the American Academy of Dermatology 88:1, pages e21-e22.
Crossref
Crossref
Erol Koç & Emel Bülbül Başkan. (2022) Combination therapies in psoriasis. TURKDERM, pages 77-79.
Crossref
Crossref
Lis Cordingley, Pauline A Nelson, Linda Davies, Darren Ashcroft, Christine Bundy, Carolyn Chew-Graham, Anna Chisholm, Jamie Elvidge, Matthew Hamilton, Rachel Hilton, Karen Kane, Christopher Keyworth, Alison Littlewood, Karina Lovell, Mark Lunt, Helen McAteer, Dionysios Ntais, Rosa Parisi, Christina Pearce, Martin Rutter, Deborah Symmons, Helen Young & Christopher EM Griffiths. (2022) Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. Programme Grants for Applied Research 10:3, pages 1-240.
Crossref
Crossref
Tamara Alessia Merkel, Alexander Navarini & Simon Mueller. (2021) Differences in phototherapy among skin diseases and genders in real‐life conditions—A retrospective analysis of the cumulative doses, numbers of sessions, side effects and costs in 561 patients. Photodermatology, Photoimmunology & Photomedicine 37:5, pages 464-473.
Crossref
Crossref
J. Berth‐Jones, L.S. Exton, E. Ladoyanni, M.F. Mohd Mustapa, V.M. Tebbs, P.D. Yesudian, N.J. Levell, P.M. McHenry, T.A. Leslie, S. Wakelin, R.Y.P. Hunasehally, M. Cork, G.A. Johnston, N. Chiang, F.S. Worsnop, A. Salim, D. Buckley, G. Petrof, N. Callachand, T. Flavell & A.A. Salad. (2019) British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018. British Journal of Dermatology 180:6, pages 1312-1338.
Crossref
Crossref
Nor Azmaniza Azizam, Aniza IsmailSaperi SulongNorazirah Md Nor. (2019) Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia. International Journal of Health Policy and Management 8:7, pages 394-402.
Crossref
Crossref
Havva Hilal AYVAZ. (2019) SIK GÖRÜLEN DERMATOLOJİK HASTALIKLARIN EKONOMİK YÜKÜTHE ECONOMIC BURDEN OF COMMON DERMATOLOGICAL DISEASES. ESTÜDAM Halk Sağlığı Dergisi 4, pages 35-51.
Crossref
Crossref
Sally Y. Tan, Elizabeth Buzney & Arash Mostaghimi. (2018) Trends in phototherapy utilization among Medicare beneficiaries in the United States, 2000 to 2015. Journal of the American Academy of Dermatology 79:4, pages 672-679.
Crossref
Crossref
F. Aubin, J. Courtois, E. Puzenat, C. Nardin, F. Castelain, F. Pelletier & C. Gastaldi‐Ménager. (2017) Phototherapy in France: quantitative data (2007–2016) from the National Health Insurance Register. Journal of the European Academy of Dermatology and Venereology 32:6.
Crossref
Crossref
Christian Kromer, Daniel Celis, Diana Sonntag & Wiebke K. Peitsch. (2018) Biologicals and small molecules in psoriasis: A systematic review of economic evaluations. PLOS ONE 13:1, pages e0189765.
Crossref
Crossref
Chong Won ChoiSeungkeol YangGwanghyun JoBo Ri KimSang Woong Youn. (2018) Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea. Annals of Dermatology 30:6, pages 668.
Crossref
Crossref
Chong Won ChoiJi Young ChoiBo Ri KimSang Woong Youn. (2018) Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis. Annals of Dermatology 30:2, pages 179.
Crossref
Crossref
A. BlauveltL. Puig, S. Chimenti, R. Vender, M. Rajagopalan, R. Romiti, L. Skov, C. Zachariae, H. YoungE. Prens, A. Cohen, J. van der WaltJ.J. Wu. (2017) Biosimilars for psoriasis: clinical studies to determine similarity. British Journal of Dermatology 177:1, pages 23-33.
Crossref
Crossref
Mandy Gutknecht, Magdalene Krensel & Matthias Augustin. (2016) Health economic analyses of psoriasis management: a systematic literature search. Archives of Dermatological Research 308:9, pages 601-616.
Crossref
Crossref
Lorenzo Mantovani, Massimo Medaglia, Patrizio Piacentini, Marcella Tricca, Gino Antonio Vena, Antonietta Vozza, Gabriella Castellino & Alessandro Roccia. (2016) Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. Dermatology and Therapy 6:2, pages 151-167.
Crossref
Crossref
Denise Küster, Alexander Nast, Sascha Gerdes, Tobias Weberschock, Gottfried Wozel, Mandy Gutknecht & Jochen Schmitt. (2016) Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting. Archives of Dermatological Research 308:4, pages 249-261.
Crossref
Crossref
Claire Shuiqing ZhangLihong YangAnthony Lin ZhangBrian H. MayJason Jingjie YuXinfeng GuoChuanjian LuCharlie Changli Xue. (2016) Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin. The Journal of Alternative and Complementary Medicine 22:3, pages 174-188.
Crossref
Crossref
Caroline P. Schaefer, Joseph C. Cappelleri, Rebecca Cheng, Jason C. Cole, Scott Guenthner, Joseph Fowler, Sandy Johnson & Carla Mamolo. (2015) Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. Journal of the American Academy of Dermatology 73:4, pages 585-593.e3.
Crossref
Crossref
Logan S. D'Souza & Michael J. Payette. (2015) Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. Journal of the American Academy of Dermatology 72:4, pages 589-598.
Crossref
Crossref
Wei Zhang, Nazrul Islam, Canice Ma & Aslam H. Anis. (2014) Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis. PharmacoEconomics 33:4, pages 327-340.
Crossref
Crossref
M.P. Hamilton, D. Ntais, C.E.M. Griffiths & L.M. Davies. (2015) Psoriasis treatment and management - a systematic review of full economic evaluations. British Journal of Dermatology 172:3, pages 574-583.
Crossref
Crossref
Giulia Ganzetti. (2015) Non-alcoholic fatty liver disease and psoriasis: So far, so near. World Journal of Hepatology 7:3, pages 315.
Crossref
Crossref
Shefton Parker, Anthony Lin Zhang, Claire Shuiqing Zhang, Greg Goodman, Zehuai Wen, Chuanjian Lu & Charlie Changlie Xue. (2014) Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial. Trials 15:1.
Crossref
Crossref
Luigi Naldi, Simone Cazzaniga & Giovanna Rao. 2014. Psoriasis. Psoriasis
11
17
.
Laura F. Sandoval, Allison Pierce & Steven R. Feldman. (2014) Systemic Therapies for Psoriasis: An Evidence-Based Update. American Journal of Clinical Dermatology 15:3, pages 165-180.
Crossref
Crossref
William Tausend, Christopher Downing & Stephen Tyring. (2014) Systematic Review of Interleukin-12, Interleukin-17, and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis. Journal of Cutaneous Medicine and Surgery 18:3, pages 156-169.
Crossref
Crossref
Medhi Moezzi, Andrea Ferencz & Dénes Lőrinczy. (2013) Evaluation of blood plasma changes by differential scanning calorimetry in psoriatic patients treated with drugs. Journal of Thermal Analysis and Calorimetry 116:2, pages 557-562.
Crossref
Crossref
Elisabeth G. Richard & Herbert Hönigsmann. (2014) Phototherapy, psoriasis, and the age of biologics. Photodermatology, Photoimmunology & Photomedicine 30:1, pages 3-7.
Crossref
Crossref
B. Zhu, E. Edson-Heredia, G.S. Cameron, W. Shen, J. Erickson, D. Shrom, P. Wang, S. Banerjee & K.B. Gordon. (2013) Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology 169:6, pages 1337-1341.
Crossref
Crossref
Anssi Mustonen, Kalle Mattila, Mauri Leino, Leena Koulu & Risto Tuominen. (2013) The Costs of Psoriasis Medications. Dermatology and Therapy 3:2, pages 169-177.
Crossref
Crossref
S. Dogra & R. Mahajan. (2013) Systemic methotrexate therapy for psoriasis: past, present and future. Clinical and Experimental Dermatology 38:6, pages 573-588.
Crossref
Crossref
Christine S. Ahn, Cheryl J. Gustafson, Laura F. Sandoval, Scott A. Davis & Steven R. Feldman. (2013) Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. American Journal of Clinical Dermatology 14:4, pages 315-326.
Crossref
Crossref
P. Lehmann. (2013) Stellenwert der Phototherapie im Zeitalter der BiologicalsPhototherapy in the era of biologicals. Der Hautarzt 64:5, pages 345-348.
Crossref
Crossref
Rishu Gupta, Ethan Levin, Tien V. Nguyen & Kanade Shinkai. (2018) Merits of Maintenance Phototherapy for Psoriasis. Psoriasis Forum 19a:1, pages 34-40.
Crossref
Crossref
Yasutomo Fujii & Takanori Sengoku. (2013) Effects of the Janus Kinase Inhibitor CP-690550 (Tofacitinib) in a Rat Model of Oxazolone-Induced Chronic Dermatitis. Pharmacology 91:3-4, pages 207-213.
Crossref
Crossref
Howa Yeung, Joy Wan, Abby S. Van Voorhees, Kristina Callis Duffin, Gerald G. Krueger, Robert E. Kalb, Jamie D. Weisman, Brian R. Sperber, Bruce A. Brod, Stephen M. Schleicher, Bruce F. BeboJr.Jr., Daniel B. Shin, Andrea B. Troxel & Joel M. Gelfand. (2013) Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. Journal of the American Academy of Dermatology 68:1, pages 64-72.
Crossref
Crossref
Thomas Herzinger, Percy Lehmann, Leonhard Zastrow, Adrian Tanew & Mark Berneburg. 2013. Fortschritte der praktischen Dermatologie und Venerologie 2012. Fortschritte der praktischen Dermatologie und Venerologie 2012
494
502
.
F. Aubin, A. Weill & H. Allemand. (2012) Phototherapy in France: quantitative data from the National Health Insurance register. British Journal of Dermatology 167:1, pages 215-216.
Crossref
Crossref